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Implante transapical de endoprótese valvada balão-expansível em posição aórtica sem circulação
extracorpórea
Off-pump transapical balloon-expandable aortic
valve endoprosthesis implantation
Abstract
Objective: The aortic valve replacement is a routine
procedure, and involves replacement of the native valve/
prosthesis. In most of the patients who undergo such
procedure the risk is acceptable, but in some cases, such
risk can justify contraindication. The minimally invasive
transcatheter aortic valve implantation without
cardiopulmonary bypass (CPB) has been shown to be viable,
with lower morbidity and mortality. The aim of this study
was to develop a catheter-mounted aortic bioprosthesis for
implantation without CPB.
Methods: After developing in animals, three patients with
high EuroSCORE underwent implantation. Case 1: patients
with bioprosthesis dysfunction; Case 2: severe aortic
stenosis; Case 3: dysfunction of aortic bioprosthesis. After
minithoracotomy and under echocardiographic and
fluoroscopic control, a balloon catheter was placed on aortic
position and inflated. After, a second balloon with valved
endoprosthesis was positioned and released under high
ventricular rate. Echocardiographic and angiographic
controls were performed and the patients were referred to
ICU.
Results: In the first case, implantation without CPB was
possible with appropriate results. The patient evolved with
improvement of ventricular function. After, this patient
developed bronchopneumonia, tracheoesophageal fistula
and died due to mediastinitis. Autopsy confirmed proper
valve positioning and leaflets preservation. The second case
showed the device migration after inflation of the balloon,
with the need for urgent median sternotomy, CPB and
conventional valve replacement. This patient evolved well
and was discharged from the ICU on the 14th postoperative
day without complications. This patient developed
respiratory infection, septic shock and died on the 60th
postoperative day. The patient from the third case underwent
successful implantation.
Conclusion: The off-pump transapical implantation of
catheter-mounted bioprosthesis was shown to be a feasible
procedure. Technical details and learning curve require
further discussion.
Descriptors: Aortic valve. Cardiopulmonary bypass. Heart
catheterization.
This study was carried out at the Federal University of São Paulo -
UNIFESP, Sao Paulo, SP, Brazil.
Correspondence address:
Diego Felipe Gaia - Rua Napoleão de Barros, 715 – 3º Andar – Cirurgia
Cardiovascular – Vila Clementino - São Paulo, SP, Brazil.
E-mail: drgaia@uol.com.br
Article received on January 20th, 2009
Article accepted on May 11th, 2009
234
GAIA, DF ET AL - Off-pump transapical balloon-expandable aortic
valve endoprosthesis implantation
Rev Bras Cir Cardiovasc 2009; 24(2): 233-238
of development and training in experimental animals, it was
possible to obtain a safe device, easy to implant and with
performance similar to that found in porcine bioprostheses
currently available in our market (Figure 1).
Based on these results, it was possible to perform the
transapical implantation of a catheter-mounted balloon-
expandable bioprosthesis without cardiopulmonary bypass
in three high surgical risk patients.
INTRODUCTION
 
The aortic valve replacement in elderly patients is a
routine procedure that usually involves replacement of the
damaged native valve or replacement of its prosthetic
impaired substitute by a bioprosthesis of different
performances and models. In most of these patients, the
surgical risk associated with the procedure is acceptable
and appropriate long-term outcome is well established [1].
The expected result can still be quite acceptable even in
octogenarians [2]. However, in some cases and especially
in reoperations, the risk predicted by various scores can
reach levels that justify the contraindication of the
procedure, up to 6% -15% [3].
In search of alternatives for this group of high-risk
patients, the minimally invasive transcatheter implantation
and without use of cardiopulmonary bypass has been
shown to be, in experimental and clinical series, a viable
alternative with lower morbidity and mortality for patients
with high surgical risk with the possibility of performing
such procedure even in reoperations [4].
Some devices such as CoreValve (CoreValve, Paris,
France) and Edwards Sapiens (Edwards Lifescience Inc,
Irvine, CA, USA) are under study, but no of them are widely
available in our country in addition to the high cost of
using.
Thus, it became necessary to develop national
technology in this field in order to facilitate the production
and use of this new knowledge. After the experimental phase
Resumo
Objetivo: A troca valvar aórtica é procedimento rotineiro,
envolve substituição da valva nativa/prótese. Na maioria
destes pacientes o risco é aceitável, porém, em alguns casos,
o risco predito pode justificar contra-indicação. O implante
de valva aórtica minimamente invasivo transcateter e sem
circulação extracorpórea (CEC) tem se mostrado viável, com
menor morbi-mortalidade. O objetivo deste trabalho foi
desenvolver bioprótese aórtica, montada em cateter, para
implante sem CEC.
Métodos: Após desenvolvimento em animais, três
pacientes com EuroSCORE elevado foram submetidos ao
implante. Caso 1: portador de bioprótese com disfunção;
Caso 2: estenose aórtica grave; Caso 3: disfunção de
bioprótese aórtica. Após minitoracotomia e sob controle
ecocardiográfico e fluoroscópico, cateter-balão foi
posicionado sobre posição aórtica e insuflado. Após, segundo
cateter-balão, com endoprótese valvada, foi posicionado e
liberado sob alta frequência ventricular. Controles
angiográficos e ecocardiográficos foram realizados e
pacientes encaminhados para UTI.
Resultados: No primeiro caso foi possível implante sem
CEC com resultados adequados. Evoluiu com melhora da
função ventricular. Cursou com broncopneumonia, fístula
traqueo-esofágica e óbito por mediastinite. Necropsia
confirmou bom posicionamento valvar e preservação dos
folhetos. O segundo caso apresentou migração do
dispositivo após insuflação do balão, necessidade de
esternotomia mediana de urgência, CEC e troca valvar
convencional. O paciente evoluiu bem, recebendo alta da
UTI 14 dias após procedimento e sem complicações. Cursou
com infecção respiratória, choque séptico e óbito no 60º
pós-operatório. O terceiro caso foi submetido a implante
com sucesso.
Conclusão: O implante de bioprótese transapical montada
em cateter sem CEC mostrou ser procedimento factível.
Detalhes técnicos e a curva de aprendizado demandam
discussão.
Descritores: Valva aórtica. Ponte cardiopulmonar.
Cateterismo cardíaco.
 Fig. 1 – Final model of aortic bioprosthesis for mounting on
balloon catheter
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catheter-mounted bioprosthesis with “oversize” of 20% was
selected and placed on the ring of the impaired
bioprosthesis through a 24F introducer (Figure 2).
Cardiac output was reduced with the aid of temporary
epimyocardial pacemaker, and then the balloon was inflated
with maximum pressure of 5 atmospheres (atm) and the
prosthesis was released (Figure 3).
CASE REPORTS
 
Case 1
64-year male patient, hypertensive and carrier of
biological prosthesis in aortic position (second prosthesis:
the first 30 years and the second 20 years ago, without
outpatient follow-up) was admitted to our emergency service
with atrial flutter with high ventricular response. After
control and reversal of arrhythmia, the patient remained
under observation at the Chest Pain Unit. After a few hours
he presented cardiogenic shock, evolving to functional
class IV (New York Heart Association) and propaedeutic
compatible with severe aortic insufficiency.
The transesophageal echocardiogram showed severe
aortic insufficiency by rupture of the bioprosthesis leaflet,
moderate pulmonary hypertension, mild-to-moderate mitral
regurgitation and moderate left ventricular dysfunction and
severe right ventricle dysfunction.
 In a few hours, the patient evolved with presentation
refractory to vasoactive drugs, lung congestion, oliguria,
worsening of renal function and need for invasive
mechanical ventilation.  The operative risk estimated by
the logistic EuroSCORE was of 54%.
It was decided to perform the valve-in-valve transcateter
transapical implant without cardiopulmonary bypass, based
on experience acquired in centers that already used to
perform the procedure, and experimental development of a
satisfactory national device tested in experimental animals.
Furthermore, meeting of consensus among the specialties
involved has occurred, informed consent from those
responsible for the patient and approval by the Research
Ethics Committee were obtained .
The implant was performed in high technology hybrid
operating room, with the presence of various devices
(hemodynamics, echocardiography, cardiopulmonary
bypass support in addition to materials and surgical
equipments and usual anesthetics).
After anesthetic induction, a small antero-lateral
thoracotomy in the fifth left intercostal space was performed
to expose the left ventricular apex. Then a double purse-
string suture supported in a Teflon felts was performed. A
6F vascular introducer was positioned with the aid of a
guidewire by puncturing in the center of the suture under
echocardiographic and fluoroscopic vision.
With the aid of a hydrophilic guidewire and a pigtail
catheter was possible to get through the aortic valve into
the descending thoracic aorta.
The initial aortography confirmed the aortic
insufficiency and favored the identification of the prosthetic
aortic valve ring and the position of the coronary ostia.
The aortic valve annulus was measured by
transesophageal echocardiography, with an internal
diameter of 19 mm. A balloon-expandable stainless steel
Fig. 2 – Left Antero-lateral minithoracotomy with exposure of the
left ventricular apex. Introducer positioned
Fig. 3 - A: Balloon inflated with expansion of the prosthesis. B:
Prosthesis positioned. Control aortography without aortic
insufficiency and free coronary ostia
After the recovery of heart rate and blood pressure,
echocardiography confirmed the absence of significant aortic
insufficiency and the control aortography showed good
prosthetics apposition and free coronary ostia (Figure 3).
The patient improved his ventricular function and the
possibility of mechanical ventilation disconnection on the
2nd postoperative day. On the 30th postoperative day,
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presented with bronchopneumonia, need for tracheostomy,
tracheo-esophageal fistula and died due to mediastinitis.
Necroscopic finding confirmed good positioning and
maintenance of valve leaflets (Figure 4).
for salvage of the prosthesis and aortic valve replacement.
The patient evolved satisfactorily and was discharged
from the intensive care unit on the 14th postoperative day.
However, on the 20th postoperative day, presented with
respiratory infection, renal failure, septic shock and death
on the 60th postoperative day.
Case 3
84-year-old male patient, with aortic bioprosthesis for 16
years, hypertensive and with nondialytic chronic renal failure,
admitted in the emergency service with congestive heart
failure in functional class IV (New York Heart Association).
Transthoracic echocardiogram showed rupture of the
bioprosthesis leaflets with aortic insufficiency and severe
left ventricular dysfunction (ejection fraction of 42%).
The cineangiocoronariography showed no coronary
lesions and aortography confirmed the aortic insufficiency.
The logistic EuroSCORE was 64%. After obtaining the
written informed consent, transapical intervention was
indicated.
  Using the technique described in case 1, under
echocardiographic, transesophageal and fluoroscopic
control, a catheter-mounted balloon bioprosthesis was
positioned on the impaired bioprosthesis and, during
reduction of cardiac output, the bioprosthesis was
expanded by balloon on the impaired bioprosthesis.
After recovering of cardiac output, echocardiography
showed the correct apposition of the prosthesis without
significant systolic gradient (25 mmHg) or central or
perivalvular aortic insufficiency. The aortography confirmed
such findings and the absence of interference with the
coronary ostia.
The patient was disconnected from mechanical
ventilation in the operating room and referred to intensive
care unit. In the immediate postoperative period, the renal
failure has become more acute, with need for temporary
dialytic therapy.
The patient is currently stable in ward. Control
echocardiogram without dysfunction, left ventricular
ejection fraction of 57%, pulmonary artery pressure of 40
mmHg, aortic transvalvular gradient of 16 mmHg and without
central or periprosthetic leak. Hospital discharge was
scheduled on the 10th postoperative day.
DISCUSSION
 
The transcateter aortic valve implantation is a new
technique and under study in various centers around the
world [4-6]. The main objective of the procedure is to
provide a satisfactory technical quality with lower morbidity
and mortality when compared to the conventional approach,
especially by avoiding the use of cardiopulmonary bypass,
median sternotomy and aortic clamping.
Fig. 4 - Necroscopic finding with good apposition between the
prosthesis and the preserved leaflets. Free coronary ostia (identified
by metal forceps)
Echocardiogram performed at the 30th postoperative day
showed no dysfunction or leak, with a maximum aortic
gradient of 39 mmHg.
Case 2
81-year-old female patient, carrier of severe aortic
stenosis with aortic maximum gradient of 72 mmHg and an
ejection fraction of 42% was admitted in the emergency
service with decompensated heart failure and need for use
of vasoactive drugs.
The patient remained in heart failure with severe
pulmonary congestion and the need for non-invasive
mechanical ventilation despite optimized medical therapy.
The logistic EuroSCORE was 60%. After obtaining the
written informed consent, the patient underwent transapical
implantation of a balloon-expandable aortic valve.
Using the same technique described in case 1, a catheter-
balloon was inflated up to its maximum pressure (5 atm) in
order to relieve the aortic stenosis. A stent with 22 mm in
diameter was expanded to its limit on the native ring under
reduction of the cardiac output by using a pacemaker.
After expansion, it could be noted by fluoroscopic view
the migration of the device into the aortic arch. Following,
it has been chosen  by median sternotomy and conversion
to conventional procedure with cardiopulmonary bypass
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Preliminary results have been encouraging, with
mortality at 30 days around 8% [4]. In addition to implants
on native valves, implants on impaired bioprostheses are
also reported [7].
Various prosthetic devices have been tested in different
centers, but the greater world experience focuses on the
Edwards Lifesciences prosthesis, which is under
investigation in a multicenter study (Partner trial- Placement
of AoRTic traNscathetER valve).
This study may demonstrate the development of a
prosthetic device of national technology, as well as other
previous national experiences, such as cardiopulmonary
bypass circuits, biological valve prostheses and aortic
stents, an outcome of the interaction between industry and
academia.
The local development of these technologies makes
possible the disclosure of high technology procedures on
our country, also allowing its access by the Unified Health
System
The three cases reported herein highlight important
points related to the procedure: its applicability and
possibility of accomplishment, with immediate success in
valve-on-valve implant and failure in implant on native
prosthesis.
Failure on implantat on native prosthesis possibly
occurred due to a learning curve in the expansion of the
balloon, which was partially within the introducer, thus
ejecting the prosthesis into the ascending aorta.
The experience proves to be essential the interaction
between different specialties, demanding cardiovascular
surgeon, hemodynamicist, echocardiographer and
anesthesiologist specially trained and involved in the
procedure. It is also necessary a hybrid surgical
environment capable of integrating surgical and
endovascular technologies with the presence of device for
fluoroscopic images acquisition (with capacity of real-time
reproduction of images) and transesophageal
echocardiogram, in addition to surgical material adapted
for radioscopic use [8] .
The transapical route was selected instead of the
transfemoral due to reports of increased mortality at 30 days
and increased occurrence of stroke by this approach [9].
There were no vascular complications related to the
access - a concern in the handling of the ventricular apex in
the elderly patients - stroke or atrioventricular block, a
complication reported specially with the self-expandable
devices [10].
This little initial experiment does not allow us to suggest
so reliable results of survival or complications because it
deals with an initial procedure and also considering the
learning curve of the procedure.
The evaluation of each of the devices, including the
reported herein, is imperative in order to determine the
correct profile of patients candidates to the procedure.
Analysis of maintenance of results, often considered
suboptimal, especially when compared to conventional
valve replacement is also essential.
Another point of discussion are the criteria used to define
the severity of the selected patient, as the EuroSCORE and
the STS score. Some authors have reported rates below the
predicted rate in respect to the complication and mortality in
aortic valve replacement in high-risk patients [2].
CONCLUSION
 
Minimally invasive transapical implant of catheter-
mounted balloon-expandable aortic bioprosthesis is a viable
technique. There is significant learning curve and need for
a team from multiple specialties in order to favor the
procedure. The long-term result, and the correct selection
of patients remain unresolved.
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Comment
Initially I would like to thank the opportunity to comment on this study
and congratulate Dr. Diego and the cardiovascular surgery team of UNIFESP
for this pioneering initiative in our country.
In addition to reporting the first three cases of implantation of transapical
aortic valve in Brazil, this study has the merit of developing together with a
national company, a device that, like many others, may allow and expand its
use in our country. Currently, CoreValve (which is a self expandable valve),
recently acquired by Medtronic, is available for clinical use in Brazil and
approved by ANVISA, and probably - at the time of submission of this article
– it has not been released for commercialization yet. The other transapical
valve available (Edwards Sapien) has not yet been released by ANVISA. Both
can be implanted either via transfemoral and transapical approach.
The study, although reporting only 3 cases, shows the feasibility of
using the device and its clinical application. The aortic valve implantation
via catheter is a new procedure and was introduced in clinical practice a few
years ago.
As emphasized in this study, in addition to the learning curve, the
interaction between the cardiovascular surgeon, the interventional cardiologist,
the echocardiographer and anesthesiologist is essential to the success of these
procedures. Ideally, the procedure should be performed in a hybrid operating
room with all surgical supplies, such as lights, surgical instruments, heart lung
machine and image equipments such as transesophageal echocardiography,
hemodynamic equipment with high-quality fluoroscopy and carbon fiber table.
As this is a procedure in its early clinical experience and under evolution, the
improvement of the devices by the industry should provide better conditions
for positioning and also repositioning of the prosthesis, resulting in increased
safety for these high-risk patients undergo conventional surgery.
I believe that the discussion on the comparison between transapical and
transfemoral approaches could be explored further. The main advantages of the
transapical approach are: antegrade insertion, associated with minimal
manipulation of the ascending aorta and arch, and lower incidence of stroke
when compared with the transfemoral approach. Furthermore, there is no
problem in vascular approach and the positioning is more accurate. On the
other hand, the transapical approach requires a mini-thoracotomy that can be
a disadvantage, specially in patients with severe pulmonary disease and those
too weak.
After these collocations,  I propose 4 questions:
1) What is the opinion of the group on the placement of a guide wire in
the femoral vein, in addition to access to the femoral artery (that is already
used for the placement of the pigtail for angiographic control)? According to
the group of Leipzig, Mohr et al, who recently published the experience of 1
year with 50 patients, this strategy allows for cardiopulmonary bypass in 2 to
3 minutes, and it has been used successfully in a patient with occlusion of the
left coronary trunk by the prosthesis (strategy called “safety net”).
2) Regarding the type of device used. A balloon expandable valved stent
was used. What are the advantages and disadvantages in relation to self-
expandable?
3) It is known that the occurrence of aortic insufficiency after these
valvular procedures by catheter is high. What is the impression of you on the
mid-term outcome such as the possibility of heart failure, hemolysis and
endocarditis?
And finally:
4) In cases with contraindications for conventional surgery in aortic
Answer
1) Due to the fact that it deals with initial experience of the group and
judging essential the presence of the “safety net” strategy aiming at improving
the safety of the procedure in eventualities and emergency conversions to a
conventional or accident rescue procedures, we used in all cases the mounted
and ready cardiopulmonary bypass circuit, in addition to the femoral artery
and vein cannulated and prepared for introduction of perfusion under full
heparinization.
Probably, with the progress of the experiment we may only allow the
placement of guide-wires, without definitive cannulation.
2) The development in experimental animals of our device consisted,
initially, of a self-expandable device. The manipulation and opening show to
be more complex when compared to balloon-expandable. Furthermore, the
literature shows that self-expandable devices may present a higher incidence
of navigation failure, in addition to not allowing the “valve-in-valve” strategy
used in some cases. Thus, we selected the balloon-expandable device for our
initial experience. Certainly, comparative studies of longer duration may
clarify which device is more safety and with better profile.
3) The transcateter procedure definitely presents a suboptimal results
when compared to conventional intervention. Most of these leaks are a result
from incomplete coaptation of the device to the valve annulus. There are no
data of long-term follow-up capable of predicting the outcome for comparison
between these insufficiencies. We can assume that due to the severity of the
selected cases, mild or mild-to-moderate insufficiencies with repercussions
can be tolerated.
4) Although there is no consensus about the best access route, it is clear
that the transfemoral route seems to be less aggressive and less invasive than
ventricular apical approach.
On availability of low profile devices with introducers below 22F or 20F,
favorable femoral iliac system, or that is, without large amount of
atherosclerosis/tortuosity and in the absence of plaques/ulcers in the aortic
arch, the transfemoral route seems to be more appropriate. However, the
profile of these patients is exactly the opposite of this situation. Thus, we
could affirm that the transapical route is most favorable to the great majority
and the transfemoral one for selected cases in the current state-of-the-art of the
devices. Clinical improvement was found but it was not significant in the
mid-term follow-up.
It is reasonable to believe that the same way we have clinically noted
patients with such insufficiency in native valves, we may act the same way in
this selected group. The presence of severe hemolysis, refractory cardiac
insufficiency or endocarditis certainly need to be approached conventionally
in face of the predicted high risk for such interventions.
stenosis, when should the transfemoral approach be indicated instead of
transfemoral transapical approach?
 I thank once again the opportunity to comment on this study.
Eduardo Keller Saadi
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